Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...

Analysts have set 12-month price targets for AbbVie, revealing an average target of $230.75, a high estimate of $255.00, and a low estimate of $205.00. Marking an increase of 2.21%, the current ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast citing strong sales of its newer immunology drugs Skyrizi and Rinvoq.

Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results ...

AbbVie announced the global Phase 3 VERONA trial evaluating Venclexta (venetoclax) in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (MDS ...